🇺🇸

US SEC Filing Intelligence

· daily

US SEC Trading Suspension Halt Orders — May 29, 2026

This intelligence digest synthesizes 9 pre-analyzed SEC filings from May 29, 2026, all concerning trading suspensions and delisting risks on US exchanges. A dominant theme is the widespread failure to meet Nasdaq's minimum stockholders' equity requirement, with three companies (Aditxt, Onfolio, HWH International) reporting negative or critically low equity, and a fourth (Actinium Pharmaceuticals) falling short of NYSE American's $4.0 million threshold. Another cluster involves delayed periodic filings (Fathom, Gulf Resources, Clean Energy Technologies, Cloudastructure), indicating systemic reporting control issues. The most acute risk is for Edible Garden AG, which faces an imminent suspension on June 5, 2026, due to ineligibility for a compliance period after multiple reverse stock splits. While most filings carry negative sentiment, Actinium Pharmaceuticals presents a mixed picture, balancing a delisting notice with a positive clinical program update, offering a potential turnaround catalyst. The aggregate data reveals a micro-cap distress pattern, with all affected companies having market capitalizations well below $100 million and exhibiting negative equity or recurring losses, signaling a high-risk environment for investors in this segment.

9 high priority 9 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 29, 2026

The 49 filings reveal a surge in corporate distress signals, with 10 companies receiving Nasdaq non-compliance or delisting notices, primarily due to late filings or equity deficiencies. Notable distress includes Aditxt (negative equity of -$35M), Edible Garden (imminent suspension), and Gulf Resources (multiple delinquencies). Capital markets activity is mixed: several companies raised debt (Xylem $1B, Kennedy-Wilson $1.8B, Navient $500M) or equity (Momentus $25M, Wellgistics $21.1M), while others like GrafTech and Solana expanded ATM programs. M&A activity continues with Cycurion acquiring Secuvant for $3M, CoStar buying Zonda for $800M, and Healthy Choice Wellness acquiring Host Digital. Insider trading data is sparse, but the high number of going concern warnings and equity issuances suggests management caution. Period-over-period comparisons are limited as most filings are event-driven, but Avalanche Treasury's net loss of $139,635 and zero cash highlight severe cash burn. The overall theme is a bifurcated market: well-capitalized firms access debt markets cheaply, while distressed micro-caps scramble for survival.

49 high priority 49 total filings
· daily

US Executive Officer Management Changes SEC — May 29, 2026

The 39 filings for May 29, 2026 reveal a significant surge in annual meeting outcomes and board/executive transitions, with a strong undercurrent of shareholder activism and financial strain. A notable 18 filings involve shareholder meetings where diverse proposals, including equity plan amendments and reverse stock splits, were passed, but several saw material dissent (e.g., Enveric's rejected stock increase, Nu Skin's narrow 70% approval on incentive plan). The sector shows a distinct pattern of insider transitions (CFO changes at Cencora, Jazz Pharma, LENSAR, and departures at Spire and Outset Medical), often structured with lengthy transition periods and advisory roles to ensure continuity. Critically, CID Holdco presents a high-risk distress signal with a temporary employee furlough, a dilutive convertible note (20% OID), and salary deferrals by executives, contrasting sharply with the stability indicated by ScanSource's YoY revenue and margin growth. The data strongly suggests a bifurcated market where stable, profitable companies are executing smooth leadership changes and rewarding shareholders, while cash-burning entities face governance challenges and existential liquidity pressures. Insider activity is absent, but forward-looking statements from Cencora (reaffirmed guidance) and the catalyst calendar from LENSAR's upcoming AGM provide actionable intelligence.

39 high priority 39 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 29, 2026

The 39 filings from May 29, 2026, primarily cover board and executive transitions (CEO, CFO, COO, director resignations/appointments), annual meeting results, and equity plan amendments. A key theme is significant insider turnover and board refreshment, which is largely neutral but includes some worrying departures (e.g., CID Holdco's entire employee furlough) and bullish stability in cash-rich firms like Cencora. Period-over-period comparisons from filings (ScanSource, Cencora) reveal modest revenue growth (2% YoY for ScanSource) and stable guidance (Cencora), but a notable number of companies (Enveric, Nu Skin, indie Semi) saw equity plan approvals face shareholder dissent, indicating governance friction. The most critical development is the severe financial distress at CID Holdco, which has furloughed all employees amid a liquidity crisis, presenting an extreme risk flag. Sector themes include a move toward majority voting for directors (First Interstate), a trend of insider talent migration from departing roles (Spire Global), and a cautious capital allocation environment with dividends holding at ScanSource.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — May 29, 2026

The May 29, 2026, US M&A landscape is dominated by the consummation of the transformative Mission Produce/Calavo Growers merger, creating a dominant North American avocado and fresh produce powerhouse, while a flurry of SPAC activity signals a potential acceleration in de-SPAC transactions. Notable period-over-period trends include a clear bifurcation in capital allocation: Tiptree is aggressively returning capital via a new $20M buyback post-divestiture, while early-stage firms like Nano Nuclear and VERAXA are securing dilutive debt and equity financing to fund growth. Insider activity is sparse but notable, with a new board appointment at Averin Capital bringing deep healthcare expertise, suggesting a targeted acquisition search. Forward-looking statements create a catalyst-rich calendar, with critical shareholder votes for Live Oak/Teamshares (June 16) and the FG Merger II/BOXABL deal, alongside monthly extension deadlines for Constellation Acquisition Corp I. The most critical development is the Mission/Calavo close, which immediately removes a public company (Calavo) and creates a combined entity with significant integration risks and potential for margin expansion through synergies, a key theme for investors to monitor in the coming quarters.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 29, 2026

Overnight filings from May 28-29, 2026 reveal a market landscape defined by aggressive capital deployment and strategic repositioning, with M&A and capital allocation dominating the news flow. The most impactful development is GameStop's unsolicited $125/share bid for eBay, a high-stakes, non-binding proposal that introduces significant regulatory and execution risk. In the avocado sector, Mission Produce completed its transformative acquisition of Calavo Growers, creating a dominant North American player but carrying substantial integration risks. On the capital allocation front, Copart aggressively repurchased $1.63 billion in shares (reducing float by 4.3%), while WisdomTree bought back convertible notes at a 68% premium, and AGNC established a new $2 billion ATM program. Period-over-period data from quarterly reports shows mixed results: Okta delivered solid 11.2% revenue growth but saw deferred revenue decline, while Copart's revenue growth slowed to 2.1% with net income slightly down. Genesco posted a seventh consecutive quarter of positive comparable sales but remains unprofitable on a GAAP basis. A notable negative signal comes from Palermo Technologies' IPO, which is self-underwritten at an arbitrary $0.10/share with no minimum offering, and Nano Nuclear Energy's acquisition of a profitable nuclear transport firm for up to $13M provides a rare revenue-generating entry point in the microreactor space. Overall, the filings suggest a market where companies are actively reshaping their capital structures and competitive positions, but with mixed underlying operational momentum.

15 high priority 20 medium 35 total filings
· daily

VA Healthcare & Services Contracts — May 28, 2026

The single contract analyzed, a $70.6 million firm-fixed-price delivery order from the Department of Veterans Affairs to EMERGENT, LLC (a subsidiary of MYTHICS, INC.), represents a purely civilian IT services win with no defense exposure. The award, for an Oracle Enterprise License Agreement under full and open competition, signals a significant multi-year revenue stream for MYTHICS, with a potential total value of $162.9 million if all options are exercised through 2030. The highest-conviction signal is the stable, non-discretionary nature of VA IT spending, though the firm-fixed-price structure introduces high performance risk. Key watch items include option exercise timing and potential contract modifications that could affect revenue realization.

1 total filings
· daily

Significant Contract Modifications ($10M+) — May 28, 2026

This digest of 15 significant contract modifications, totaling $1.09 billion, reveals a purely civilian procurement landscape with zero defense-related awards, underscoring a pronounced shift in federal spending toward non-DOD agencies. The dominant themes are civilian IT modernization (GSA, DHS, State, VA) and health/biodefense R&D (HHS/BARDA), with the highest-conviction signal being Booz Allen Hamilton's $218.7M cost-plus-award-fee delivery order from GSA, which offers stable, low-risk revenue visibility. A key risk is the high concentration of awards to small, private, or nonprofit entities (e.g., Venatorx, V3GATE, Zen Strategics), limiting direct public market exposure, while the absence of defense contracts may signal a temporary lull or a broader civilian spending priority shift that warrants monitoring.

15 total filings
· daily

Contract Deobligations Alert — May 28, 2026

This digest of 15 government contracts, totaling $1.09 billion, is entirely civilian in nature, with zero defense-related awards. The dominant theme is IT modernization and professional services, led by Booz Allen Hamilton's $218.7M GSA engineering services award (potential $626.5M) and Venatorx Pharmaceuticals' $106.6M BARDA R&D contract. The highest-conviction signal is Booz Allen's cost-plus structure, which provides low-risk, stable revenue visibility. A key watch item is the high concentration of awards to small and privately-held firms (e.g., V3GATE, Four Points Technology, Zen Strategics), which limits direct public equity exposure and introduces execution risk on firm-fixed-price contracts.

15 total filings
· daily

Contract Option Exercises — May 28, 2026

This digest covers 15 civilian government contract option exercises totaling $1.09 billion, with zero defense-related awards. The dominant theme is civilian IT modernization and professional services, led by GSA FEDSIM ($218.7M to Booz Allen Hamilton) and BARDA health R&D ($106.6M to Venatorx Pharmaceuticals). The highest-conviction signal is Booz Allen's cost-plus contract, offering stable, low-risk revenue visibility through 2028. A key risk is the concentration of firm-fixed-price awards (e.g., Emergent LLC's $70.6M VA contract) that carry execution risk, and the absence of defense exposure limits tailwinds from NDAA priorities.

15 total filings
· daily

Federal Professional Services Contracts — May 28, 2026

This digest covers two civilian agency contracts totaling $290.2M in obligations, with zero defense-related awards. The dominant theme is stable, multi-year professional services demand from GSA and DHS, with Booz Allen Hamilton's $218.7M GSA FEDSIM award (potential $626.5M) representing the highest-conviction signal—a cost-plus structure that de-risks execution. Noblis's $71.5M DHS CWMD contract shows strong utilization but carries medium pricing risk due to time-and-materials terms. Key risk: both contracts are civilian, making them more vulnerable to discretionary budget cuts or CR-driven delays than defense programs. Watch for Booz Allen option exercises in FY2024-2028 and Noblis re-compete risk as its contract ends May 2026.

2 total filings
· daily

Federal IT & Cybersecurity Contracts — May 28, 2026

This digest covers 7 civilian federal IT and cybersecurity contracts totaling $423.7 million in obligations, with zero defense-related awards. The dominant theme is civilian agency enterprise software and cloud services modernization, led by the Department of State and Department of Veterans Affairs. The highest-conviction signal is EMERGENT, LLC (MYTHICS, INC.) winning two large Oracle license awards worth a combined $122.7 million from the VA and State Department, signaling strong recurring revenue visibility. A key risk is the heavy concentration of awards to small and private firms—V3GATE, LLC, Four Points Technology, and Zen Strategics LLC—which limits direct public market exposure and introduces execution and revenue concentration risks.

7 total filings
· daily

All HHS Contracts — May 28, 2026

This single-record period captures a $106.6 million civilian R&D contract from BARDA (HHS) to Venatorx Pharmaceuticals Inc., a small biotech firm, signaling an urgent and well-funded push for health security experimental development. With zero defense-related awards, the sole signal is purely civilian and bullish, driven by a full-and-open competitive win that validates Venatorx’s platform. The contract’s cost-sharing structure introduces medium execution risk, as Venatorx must co-invest alongside the government, but the multi-year commitment through 2025 provides visible, non-dilutive revenue. The key watch item is the exercise of options, which will determine whether the total value grows from $106.6M to $146.9M, and the burn rate relative to the $36.7M currently outlayed.

1 total filings
· daily

General Federal Contracts — May 28, 2026

This digest covers 15 federal contracts totaling $1.09 billion, all awarded by civilian agencies (0% defense-related), signaling a robust non-DOD procurement environment. The dominant themes are IT services modernization (Booz Allen Hamilton, Peraton, Emergent, V3GATE) and health/biodefense R&D (Venatorx Pharmaceuticals), with the highest-conviction signal being Booz Allen Hamilton's $218.7M cost-plus-award-fee delivery order from GSA, which offers stable, lower-risk revenue and significant option upside to $626.5M. A key risk is the high concentration of awards to small, private, or nonprofit entities (e.g., Venatorx, Noblis, Mission for Essential Drugs), limiting direct public equity exposure, while the lack of defense contracts reduces sensitivity to NDAA-driven durability but increases vulnerability to civilian budget uncertainty under a Continuing Resolution.

15 total filings
· daily

All NASA Contracts — May 28, 2026

This digest covers a single $51.4M NASA contract awarded to AGILE DECISION SCIENCES, LLC, a subsidiary of the ARCTIC SLOPE REGIONAL CORPORATION, for administrative and IT support services at NASA Headquarters. The contract is entirely civilian, with zero defense-related exposure, and carries a bullish signal strength of 7/10. The highest-conviction signal is the stable, recurring revenue stream through 2026 under a cost-plus-fixed-fee structure, which limits margin upside but provides predictable cash flows. A key risk is the concentration of this revenue within the parent company's portfolio and the eventual expiration of 8(a) program eligibility, which could increase competitive pressure on future awards.

1 total filings